120 related articles for article (PubMed ID: 22015641)
1. Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy.
Song TJ; Haddad D; Adusumilli P; Kim T; Stiles B; Hezel M; Socci ND; Gönen M; Fong Y
Cancer Gene Ther; 2012 Jan; 19(1):38-48. PubMed ID: 22015641
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.
Song TJ; Eisenberg DP; Adusumilli PS; Hezel M; Fong Y
J Gastrointest Surg; 2006 Apr; 10(4):532-42. PubMed ID: 16627219
[TBL] [Abstract][Full Text] [Related]
4. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
5. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
6. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Activity of a Novel Influenza A Virus Carrying Granulocyte-Macrophage Colony-Stimulating Factor in Hepatocellular Carcinoma.
Penghui Y; Fang S; Ruilan W; Guanglin L; Hongjing G; Yueqiang D; Zhongpeng Z; Xiaolan Y; Zhaohai W; Shaogeng Z; Xiliang W
Hum Gene Ther; 2019 Mar; 30(3):330-338. PubMed ID: 30205709
[TBL] [Abstract][Full Text] [Related]
8. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
9. Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma.
Zhang KJ; Qian J; Wang SB; Yang Y
J Biomed Sci; 2012 Feb; 19(1):20. PubMed ID: 22321574
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
[TBL] [Abstract][Full Text] [Related]
12. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
Pin RH; Reinblatt M; Fong Y
Ann Surg; 2004 Oct; 240(4):659-65; discussion 665-6. PubMed ID: 15383793
[TBL] [Abstract][Full Text] [Related]
13. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
14. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
15. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases.
Reinblatt M; Pin RH; Federoff HJ; Fong Y
Ann Surg; 2004 Jun; 239(6):892-9; discussion 899-902. PubMed ID: 15166969
[TBL] [Abstract][Full Text] [Related]
16. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
[TBL] [Abstract][Full Text] [Related]
17. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
[TBL] [Abstract][Full Text] [Related]
19. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
